Skip to main content
ADIMMUNE CORPORATION logo

ADIMMUNE CORPORATION - Investor Relations & Filings

Listed IPO May 2012
Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,818 across all filing types
Latest filing 2026-07-13 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4142

Key figures FY2025

Period ended 2025-12-31 · TWD
Headline annual figures for ADIMMUNE CORPORATION, fiscal year 2025, reported in TWD, with the source filing for each figure.
Total Revenues TWD 1.40B per the Annual Report filed 2026-06-17
Net Income TWD -329.77M per the Annual Report filed 2026-06-17
Total Assets TWD 8.19B per the Annual Report filed 2026-06-17
Total Equity TWD 5.05B per the Annual Report filed 2026-06-17
Cash from Ops TWD -5.45M per the Audit Report / Information filed 2026-05-14

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ADIMMUNE CORPORATION

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_4142_AIA.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report for Adimmune Corporation for the period ended March 31, 2026. It includes consolidated balance sheets, statements of comprehensive income, and an independent auditors' review report. As it covers a period shorter than a full fiscal year and contains substantive financial statements, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-07-13 English
115年6月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure from a Taiwanese listed company (國光生) regarding 'Endorsements/Guarantees' and 'Loans of Funds' (背書保證與資金貸與). These are standard regulatory disclosures required by the Taiwan Stock Exchange (TWSE) for listed companies to report their financial risk exposure. Since this is a recurring regulatory disclosure of financial status rather than a quarterly/annual financial report, an earnings release, or a specific corporate action, it falls under the general regulatory filing category.
2026-07-09 Chinese
115年6月營業收入
Earnings Release Classification · 95% confidence The document is a monthly revenue report (營業收入) provided by a listed company (國光生) via the Taiwan Stock Exchange's Market Observation Post System (MOPS). It contains specific financial data for the month of June 115 (Republic of China calendar), including current month revenue, year-to-date figures, and year-over-year comparisons. Since this is a recurring monthly financial disclosure of revenue results rather than a full quarterly or annual report, it falls under the Earnings Release (ER) category as it provides key financial highlights for a specific period. H1 2026
2026-07-09 Chinese
115年06月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document is a monthly report from the Taiwan Stock Exchange's Market Observation Post System (MOPS) detailing changes in shareholdings by company insiders (directors, managers, and their spouses/minor children) for the company 'Adimmune Corporation' (國光生). The content explicitly lists names, positions, and share counts, which is the standard format for 'Director's Dealing' or 'Insider Trading' reports. In the provided classification schema, 'DIRS' (Director's Dealing) is the correct category for reports of personal share transactions by company directors and executives.
2026-07-07 Chinese
115年06月董事會成員及持股
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure of shareholdings for directors, supervisors, and major shareholders of Adimmune Corporation (國光生物科技股份有限公司), sourced from the Taiwan Stock Exchange's Market Observation Post System (MOPS). This type of filing is a standard regulatory requirement in Taiwan for reporting insider shareholdings and is classified under 'Regulatory Filings' (RNS) as it does not represent a specific transaction by a single director (DIRS) or a change in major shareholding (MRQ), but rather a periodic regulatory disclosure of the entire board's holdings.
2026-07-07 Chinese
115年年報及股東會資料 — 2026_4142_20260604F05.pdf
AGM Information Classification · 95% confidence The document is titled '115年年報及股東會資料' (2026 Annual Report and Shareholders' Meeting Materials). It contains the minutes of the Annual General Meeting (AGM), the business report, the audit committee report, and the audited financial statements for the fiscal year 114 (2025). While it includes financial statements, the primary purpose of this specific document is to provide the materials for the Annual General Meeting, including the agenda, voting results, and management reports presented to shareholders. Therefore, it is classified as AGM Information. FY 2025
2026-06-17 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.